Evolocumab mechanism to reduce LDL cholesterol (Homo sapiens)
From WikiPathways
Description
Evolocumab (Repatha) is an injectable monoclonal antibody that reduces LDL cholesterol levels. A limited quantity of LDL cholesterol is extracted from circulative blood when PCSK9-bound LDLR is degraded upon internalization in liver cells. Evolocumab competitively binds PCSK9 away from LDLR complexes, which allows LDLR to be recycled, returning to the surface and clearing additional molecules of LDL cholesterol.
Quality Tags
Ontology Terms
Bibliography
- Dorey, Emma; ''PCSK9 inhibitors: the next cholesterol-lowering blockbusters?''; The Pharmaceutical Journal, 2015 DOI Scholia
History
View all... |
External references
DataNodes
Name | Type | Database reference | Comment |
---|---|---|---|
Evolocumab | Metabolite | Q15623825 (Wikidata) | |
LDL-C | Metabolite | CHEBI:47774 (ChEBI) | |
LDLR | GeneProduct | ENSG00000130164 (Ensembl) | |
PCSK9 | GeneProduct | ENSG00000169174 (Ensembl) |
Annotated Interactions
No annotated interactions